ALGS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aligos Therapeutics Inc (ALGS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock's technical indicators are neutral to slightly bearish, financial performance is weak, and there are no immediate positive catalysts or strong trading signals to justify a purchase. Analysts have a positive long-term outlook, but the company's fundamentals and lack of recent news or significant events do not support an immediate buy decision.
The MACD histogram is slightly positive at 0.00183, but the RSI is neutral at 49.406. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below the pivot level of 7.285. Support levels are at 6.713 and 6.359, while resistance levels are at 7.858 and 8.212. Overall, the technical indicators suggest a neutral to bearish trend.
Analysts have initiated coverage with Buy ratings and high price targets, citing potential differentiation in the company's hepatitis B treatment pipeline. Hedge funds have increased their buying activity by 162.30% over the last quarter.
The company's financial performance in Q4 2025 was weak, with significant YoY declines in revenue (-73.13%), net income (-75.80%), and EPS (-85.40%). There is no recent news or significant event-driven catalysts. Insider trading activity is neutral, and there is no recent congress trading data.
In Q4 2025, revenue dropped to $169,000 (-73.13% YoY), net income dropped to -$19,881,000 (-75.80% YoY), and EPS dropped to -1.91 (-85.40% YoY). Gross margin remained stable at 100%. Overall, the financials indicate poor performance with no growth trends.
Analysts have a positive outlook with Buy ratings and price targets ranging from $20 to $48. They highlight the potential of the company's hepatitis B treatment pipeline but acknowledge risks and prior class failures. The stock is trading near its cash levels, which could present a long-term opportunity, but the near-term risk/reward is asymmetric.
